Table of Contents Author Guidelines Submit a Manuscript
Autoimmune Diseases
Volume 2011 (2011), Article ID 973808, 5 pages
http://dx.doi.org/10.4061/2011/973808
Review Article

Lambert-Eaton Myasthenic Syndrome; Pathogenesis, Diagnosis, and Therapy

1Department of Clinical Medicine, University of Bergen, 5020 Bergen, Norway
2Department of Neurology, Haukeland University Hospital, 5021 Bergen, Norway

Received 26 May 2011; Accepted 4 August 2011

Academic Editor: Johan A. Aarli

Copyright © 2011 Nils Erik Gilhus. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. E. H. Lambert, L. M. Eaton, and E. D. Rooke, “Defect of neuromuscular conduction associated with malignant neoplasms,” American Journal of Physiology, vol. 187, pp. 612–613, 1956. View at Google Scholar
  2. P. W. Wirtz, M. G. Nijnuis, M. Sotodeh et al., “The epidemiology of myasthenia gravis, Lambert-Eaton myasthenic syndrome and their associated tumours in the northern part of the province of South Holland,” Journal of Neurology, vol. 250, no. 6, pp. 698–701, 2003. View at Publisher · View at Google Scholar · View at Scopus
  3. M. J. Titulaer and J. J. G. M. Verschuuren, “Lambert-Eaton myasthenic syndrome: tumor versus nontumor forms,” Annals of the New York Academy of Sciences, vol. 1132, pp. 129–134, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. P. J. Lorenzoni, R. H. Scola, C. S. K. Kay, S. F. Parolin, and L. C. Werneck, “Non-paraneoplastic Lambert-Eaton myasthenic syndrome,” Arq Neuropsiquiatr, vol. 68, no. 6, pp. 849–854, 2010. View at Google Scholar
  5. G. M. Elrington, N. M. F. Murray, S. G. Spiro, and J. Newsom-Davis, “Neurological paraneoplastic syndromes in patients with small cell lung cancer,” Journal of Neurology Neurosurgery and Psychiatry, vol. 54, no. 9, pp. 764–767, 1991. View at Google Scholar · View at Scopus
  6. M. J. Titulaer, R. Klooster, M. Potman et al., “SOX antibodies in small-cell lung cancer and Lambert-Eaton myasthenic syndrome: frequency and relation with survival,” Journal of Clinical Oncology, vol. 27, no. 26, pp. 4260–4267, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. M. J. Titulaer, P. W. Wirtz, J. B. M. Kuks et al., “The Lambert-Eaton myasthenic syndrome 1988–2008: a clinical picture in 97 patients,” Journal of Neuroimmunology, vol. 201-202, pp. 153–158, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. H. L. Pellkofer, L. Armbruster, R. Linke, F. Schumm, and R. Voltz, “Managing non-paraneoplastic Lambert-Eaton myasthenic syndrome: clinical characteristics in 25 German patients,” Journal of Neuroimmunology, vol. 217, no. 1-2, pp. 90–94, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. A. Quartel, S. Turbeville, and D. Lounsbury, “Current therapy for Lambert-Eaton myasthenic syndrome: development of 3,4-diaminopyridine phosphate salt as first-line symptomatic treatment,” Current Medical Research and Opinion, vol. 26, no. 6, pp. 1363–1375, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. S. A. Waterman, B. Lang, and J. Newsom-Davis, “Effect of Lambert-Eaton myasthenic syndrome antibodies on autonomic neurons in the mouse,” Annals of Neurology, vol. 42, no. 2, pp. 147–156, 1997. View at Publisher · View at Google Scholar · View at Scopus
  11. M. Takamori, “Lambert-Eaton myasthenic syndrome: search for alternative autoimmune targets and possible compensatory mechanisms based on presynaptic calcium homeostasis,” Journal of Neuroimmunology, vol. 201-202, pp. 145–152, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. F. J. Urbano, M. R. Pagani, and O. Uchitel, “Calcium channels, neuromuscular synaptic transmission and neurological diseases,” Journal of Neuroimmunology, vol. 201-202, pp. 136–144, 2008. View at Google Scholar
  13. M. Motomura, I. Johnston, B. Lang, A. Vincent, and J. Newsom-Davis, “An improved diagnostic assay for Lambert-Eaton myasthenic syndrome,” Journal of Neurology Neurosurgery and Psychiatry, vol. 58, no. 1, pp. 85–87, 1995. View at Google Scholar · View at Scopus
  14. J. J. Verschuuren, J. Dalmau, R. Tunkel et al., “Antibodies against the calcium channel beta-subunit in Lambert-Eaton myasthenic syndrome,” Neurology, vol. 50, no. 2, pp. 475–479, 1998. View at Google Scholar · View at Scopus
  15. H. L. Pellkofer, L. Armbruster, M. Krumbholz et al., “Lambert-Eaton myasthenic syndrome differential reactivity of tumor versus non-tumor patients to subunits of the voltage-gated calcium channel,” Journal of Neuroimmunology, vol. 204, no. 1-2, pp. 136–139, 2008. View at Publisher · View at Google Scholar · View at Scopus
  16. T. Tani, K. Tanaka, J. Idezuka, and M. Nishizawa, “Regulatory T cells in paraneoplastic neurological syndromes,” Journal of Neuroimmunology, vol. 196, no. 1-2, pp. 166–169, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. P. W. Wirtz, B. O. Roep, G. M. T. Schreuder et al., “HLA class I and II in Lambert-Eaton myasthenic syndrome without associated tumor,” Human Immunology, vol. 62, no. 8, pp. 809–813, 2001. View at Publisher · View at Google Scholar · View at Scopus
  18. A. R. Punga, I. Nygren, H. Askmark, and E. V. Stålberg, “Monozygous twins with neuromuscular transmission defects at opposite sides of the motor endplate,” Acta Neurologica Scandinavica, vol. 119, no. 3, pp. 207–211, 2009. View at Publisher · View at Google Scholar · View at Scopus
  19. C. S. Morris, M. M. Esiri, A. Marx, and J. Newsom-Davis, “Immunocytochemical characteristics of small cell lung carcinoma associated with the Lambert-Eaton myasthenic syndrome,” American Journal of Pathology, vol. 140, no. 4, pp. 839–845, 1992. View at Google Scholar · View at Scopus
  20. A. Roberts, S. Perera, B. Lang, A. Vincent, and J. Newsom-Davis, “Paraneoplastic myasthenic syndrome IgG inhibits 45Ca2+ flux in a human small cell carcinoma line,” Nature, vol. 317, pp. 737–739, 1985. View at Publisher · View at Google Scholar
  21. M. J. Titulaer, R. Soffietti, J. Dalmau et al., “Screening for tumours in paraneoplastic syndromes: report of an EFNS task force,” European Journal of Neurology, vol. 18, no. 1, pp. 19–27, 2011. View at Publisher · View at Google Scholar · View at Scopus
  22. M. J. Titulaer, P. Maddison, J. K. Sont et al., “Clinical Dutch-English Lambert-Eaton myasthenic syndrome (LEMS) tumor-association prediction score accurately predicts small-cell lung cancer in the LEMS,” Journal of Clinical Oncology, vol. 29, no. 7, pp. 902–908, 2011;:. View at Publisher · View at Google Scholar
  23. W. P. Mason, F. Graus, B. Lang et al., “Small-cell lung cancer, paraneoplastic cerebellar degeneration and the Lambert-Eaton myasthenic syndrome,” Brain, vol. 120, no. 8, pp. 1279–1300, 1997. View at Publisher · View at Google Scholar · View at Scopus
  24. L. Romics, B. McNamara, P. A. Cronin, M. E. O'Brien, N. Relihan, and H. P. Redmond, “Unusual paraneoplastic syndromes of breast carcinoma: a combination of cerebellar degeneration and Lambert-Eaton myasthenic syndrome,” Irish Journal of Medical Science, vol. 180, no. 2, pp. 569–571, 2011. View at Publisher · View at Google Scholar · View at Scopus
  25. P. J. Lorenzoni, R. H. Scola, B. Lang et al., “Cerebellar ataxia in non-paraneoplastic Lambert-Eaton myasthenic syndrome,” Journal of the Neurological Sciences, vol. 270, no. 1-2, pp. 194–196, 2008. View at Publisher · View at Google Scholar · View at Scopus
  26. G. O. Skeie, S. Apostolski, A. Evoli et al., “Guidelines for treatment of autoimmune neuromuscular transmission disorders,” European Journal of Neurology, vol. 17, no. 7, pp. 893–902, 2010. View at Publisher · View at Google Scholar · View at Scopus
  27. Z. Argov, “Management of myasthenic conditions: nonimmune issues,” Current Opinion in Neurology, vol. 22, no. 5, pp. 493–497, 2009. View at Publisher · View at Google Scholar · View at Scopus
  28. J. Spillane, D. J. Beeson, and D. M. Kullmann, “Myasthenia and related disorders of the neuromuscular junction,” Journal of Neurology, Neurosurgery and Psychiatry, vol. 81, no. 8, pp. 850–857, 2010. View at Publisher · View at Google Scholar · View at Scopus
  29. P. Maddison and J. Newsom-Davis, “Treatment for Lambert-Eaton myasthenic syndrome,” The Cochrane Library, no. 2, article CD003279, 2011. View at Publisher · View at Google Scholar
  30. M. B. Weimer and J. Wong, “Lambert-Eaton myastenic syndrome,” Current Treatment Options in Neurology, vol. 11, pp. 77–84, 2009. View at Google Scholar
  31. P. Maddison, J. McConville, M. E. Farrugia et al., “The use of rituximab in myasthenia gravis and Lambert-Eaton myasthenic syndrome,” Journal of Neurology, Neurosurgery and Psychiatry, vol. 82, no. 6, pp. 671–673, 2011. View at Google Scholar
  32. I. Elovaara, S. Apostolski, P. van Doorn et al., “EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases,” European Journal of Neurology, vol. 15, no. 9, pp. 893–908, 2008. View at Publisher · View at Google Scholar · View at Scopus
  33. U. Reuner, G. Kamin, G. Ramantani, H. Reichmann, and J. Dinger, “Transient neonatal Lambert-Eaton syndrome,” Journal of Neurology, vol. 255, no. 11, pp. 1827–1828, 2008. View at Publisher · View at Google Scholar · View at Scopus